Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
01 10 2019
Historique:
pubmed: 2 8 2019
medline: 11 6 2020
entrez: 2 8 2019
Statut: ppublish

Résumé

Cardiovascular disease (CVD) is a major source of morbidity and mortality among breast cancer survivors. Although body mass index (BMI) is associated with CVD risk, adipose tissue distribution may better identify patients with a high risk of CVD after breast cancer. Among 2,943 patients with nonmetastatic breast cancer without prior CVD, we used International Classification of Diseases (9th and 10th revisions) codes to identify incidence of nonfatal stroke, myocardial infarction, heart failure, or CVD death. From clinically acquired computed tomography scans obtained near diagnosis, we measured visceral adiposity (centimeters squared), subcutaneous adiposity (centimeters squared), and intramuscular adiposity (fatty infiltration into muscle [Hounsfield Units, scored inversely]). We estimated hazard ratios (HRs) and 95% CIs per SD increase in adiposity accounting for competing risks and adjusting for demographics, smoking, cancer treatment, and pre-existing CVD risk factors. Mean (SD) age was 56 (12) years. Over a median follow-up of 6 years, 328 CVD events occurred. Each SD increase in visceral or intramuscular adiposity was associated with an increase in CVD risk (HR, 1.15 [95% CI, 1.03 to 1.29] and HR, 1.21 [95% CI, 1.06 to 1.37]), respectively). Excess visceral and intramuscular adiposity occurred across all BMI categories. Among normal-weight patients, each SD greater visceral adiposity increased CVD risk by 70% (HR, 1.70 [95% CI, 1.10 to 2.62]). Visceral and intramuscular adiposity were associated with increased CVD incidence after breast cancer diagnosis, independent of pre-existing CVD risk factors and cancer treatments. The increased CVD incidence among normal-weight patients with greater visceral adiposity would go undetected with BMI alone. Measures of adipose tissue distribution may help identify high-risk patients and tailor CVD prevention strategies.

Identifiants

pubmed: 31369302
doi: 10.1200/JCO.19.00286
pmc: PMC7001794
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2528-2536

Subventions

Organisme : NCI NIH HHS
ID : K01 CA226155
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184953
Pays : United States

Références

Obes Res. 1995 Jan;3(1):73-95
pubmed: 7712363
J Am Coll Cardiol. 2013 Sep 3;62(10):921-5
pubmed: 23850922
N Engl J Med. 2010 Jun 10;362(23):2155-65
pubmed: 20558366
Breast Cancer Res. 2011 Jun 20;13(3):R64
pubmed: 21689398
J Clin Endocrinol Metab. 2010 Dec;95(12):5419-26
pubmed: 20843952
JAMA. 2013 Jan 2;309(1):87-8
pubmed: 23280230
Proc Nutr Soc. 2016 May;75(2):188-98
pubmed: 26743210
Circulation. 2015 Oct 27;132(17):1639-47
pubmed: 26294660
Nutr Metab Cardiovasc Dis. 2017 Oct;27(10):881-889
pubmed: 28851556
Am J Epidemiol. 2004 Oct 15;160(8):741-9
pubmed: 15466496
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1403-9
pubmed: 19366908
Obesity (Silver Spring). 2009 May;17(5):1062-9
pubmed: 19165157
Am J Clin Nutr. 2014 May;99(5):999-1005
pubmed: 24572565
Obesity (Silver Spring). 2007 Nov;15(11):2688-98
pubmed: 18070760
Trends Pharmacol Sci. 2015 Jun;36(6):326-48
pubmed: 25895646
Cancer. 2004 Oct 15;101(8):1712-9
pubmed: 15386307
Br J Cancer. 2005 Aug;93 Suppl 1:S23-7
pubmed: 16100522
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Ann Intern Med. 2015 Dec 1;163(11):827-35
pubmed: 26551006
Annu Rev Nutr. 2010 Aug 21;30:13-34
pubmed: 20373917
Br J Nutr. 1991 Mar;65(2):105-14
pubmed: 2043597
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1081-91
pubmed: 16446057
EJC Suppl. 2014 Jun;12(1):18-28
pubmed: 26217163
Circ Cardiovasc Imaging. 2016 Apr;9(4):e004043
pubmed: 27072302
Eur J Clin Nutr. 2000 Jun;54 Suppl 3:S26-32
pubmed: 11041072
Obesity (Silver Spring). 2010 Nov;18(11):2191-8
pubmed: 20339361
JMIR Med Inform. 2016 Feb 04;4(1):e2
pubmed: 26846251
Diabetes Obes Metab. 2007 Jul;9(4):498-505
pubmed: 17587392
Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):345-51
pubmed: 25106000
Acta Physiol (Oxf). 2014 Mar;210(3):489-97
pubmed: 24393306
IEEE Trans Med Imaging. 2016 Feb;35(2):512-20
pubmed: 26415164
J Clin Oncol. 2007 May 20;25(15):2100-6
pubmed: 17513816
JACC Cardiovasc Imaging. 2014 Dec;7(12):1221-35
pubmed: 25440591
Breast Cancer Res Treat. 2012 Feb;131(3):907-14
pubmed: 22042368
Epidemiology. 2016 Jan;27(1):6-13
pubmed: 26414938
Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1468-73
pubmed: 17627012
JAMA Oncol. 2018 Jun 1;4(6):798-804
pubmed: 29621380
Diabetes Care. 1999 Nov;22(11):1808-12
pubmed: 10546012
Circulation. 2007 Jul 3;116(1):39-48
pubmed: 17576866
Diabetes Care. 2003 Feb;26(2):372-9
pubmed: 12547865
Curr Opin Clin Nutr Metab Care. 2017 Sep;20(5):314-321
pubmed: 28768291
Int J Obes (Lond). 2008 Jun;32(6):959-66
pubmed: 18283284
Breast Cancer Res Treat. 2014 Nov;148(2):249-68
pubmed: 25324019
J Clin Endocrinol Metab. 2017 Nov 1;102(11):4173-4183
pubmed: 28938406
Breast Cancer Res Treat. 2014 Jan;143(2):219-26
pubmed: 24337598
Obes Rev. 2016 Mar;17(3):262-75
pubmed: 26663309
Br J Cancer. 2003 Sep 1;89(5):781-6
pubmed: 12942105
Eur Heart J. 2007 Sep;28(17):2087-93
pubmed: 17626030
Breast Cancer Res Treat. 2012 Jan;131(2):679-90
pubmed: 21953007
Eur J Clin Nutr. 1998 Nov;52(11):779-83
pubmed: 9846588
Abdom Radiol (NY). 2017 Sep;42(9):2369-2375
pubmed: 28389787

Auteurs

Elizabeth M Cespedes Feliciano (EM)

Kaiser Permanente Northern California, Oakland, CA.

Wendy Y Chen (WY)

Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Dana Farber Cancer Institute, Boston, MA.

Patrick T Bradshaw (PT)

University of California, Berkeley, Berkeley, CA.

Carla M Prado (CM)

University of Alberta, Edmonton, Alberta, Canada.

Stacey Alexeeff (S)

Kaiser Permanente Northern California, Oakland, CA.

Kathleen B Albers (KB)

Kaiser Permanente Northern California, Oakland, CA.

Adrienne L Castillo (AL)

Kaiser Permanente Northern California, Oakland, CA.

Bette J Caan (BJ)

Kaiser Permanente Northern California, Oakland, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH